---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-098668"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2023-09-06T23:59:59+00:00"
generated_at: "2026-06-10T23:25:53.773568+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Hepion CMO Todd Hobbs resigns; Stephen Harrison appointed Consultant Medical Director

## Summary
- Dr. Todd Hobbs resigned as CMO effective September 29, 2023; resignation not due to any disagreement with the Company.
- Company appointed Dr. Stephen Harrison as Consultant Medical Director; he chairs the Scientific Advisory Board.
- Dr. Harrison previously served as Consultant Medical Director from Oct 2019 to Feb 2021; leads Pinnacle Clinical Research.

## SEC filing metadata
- accession: 0001104659-23-098668
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2023-09-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000110465923098668/0001104659-23-098668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000110465923098668/tm2325511d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-098668
- JSON: https://secwatch.observer/filing/0001104659-23-098668.json
- Plain text: https://secwatch.observer/filing/0001104659-23-098668.txt

## Key facts
- Executive change
  Stephen Harrison was appointed as Consultant Medical Director at Hepion Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Consultant Medical Director
  source text: On September 6, 2023, the Company appointed Stephen Harrison, M.D., the Company’s current Chairman of the Company’s Scientific Advisory Board, as Consultant Medical Director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000110465923098668/0001104659-23-098668-index.htm
- Executive change
  Todd Hobbs resigned as Chief Medical Officer at Hepion Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On August 30, 2023, Dr. Todd Hobbs, the Chief Medical Officer (“CMO”), of Hepion Pharmaceuticals, Inc. (the “Company”) provided notice to the Company of his resignation as CMO, effective September 29, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000110465923098668/0001104659-23-098668-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.